Risk of congenital cytomegalovirus infection among HIV-exposed uninfected infants is not decreased by maternal nelfinavir use during pregnancy

Journal of Medical Virology

Volumn 88, Issue 6, 2016, Pages 1051-1058

  Gantt, Soren ^a,b   Leister, Erin ^c   Jacobsen, Denise L ^c   Boucoiran, Isabelle ^d,e   Huang, Meei Li ^b,f   Jerome, Keith R ^b,f   Jourdain, Gonzague ^g,h   Ngo Giang Huong, Nicole ^g,h   Burchett, Sandra ⁱ   Frenkel, Lisa ^f,j  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b USA   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d UNIVERSITY OF MONTREAL   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY OF WASHINGTON   (United States)

^g Research Unit 024 French Institute of Research for Development (IRD)   (France)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

more..

Author keywords

Congenital cytomegalovirus infection; HIV exposed uninfected infants; Nelfinavir

Indexed keywords

NELFINAVIR; NEVIRAPINE; PLACEBO; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; VIRUS DNA;

ARTICLE; BIRTH WEIGHT; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONGENITAL CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS INFECTION; DRUG USE; FEMALE; GESTATION PERIOD; GESTATIONAL AGE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PLACENTAL TRANSFER; PREGNANCY OUTCOME; PREVALENCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TREATMENT DURATION; ADULT; BLOOD; CD4+ T LYMPHOCYTE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GENETICS; HIV INFECTIONS; IMMUNOLOGY; MOTHER; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; TRANSMISSION; VERTICAL TRANSMISSION; VIROLOGY; YOUNG ADULT;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MOTHERS; NELFINAVIR; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; RISK FACTORS; YOUNG ADULT;

EID: 84947716724     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24420     Document Type: Article

References (40)

1. Boeckh M, Huang M, Ferrenberg J, Stevens-Ayers T, Stensland L, Nichols WG, Corey L. 2004. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 42:1142-1148.
2. Boppana SB, Ross SA, Novak Z, Shimamura M, Tolan RW Jr, Palmer AL, Ahmed A, Michaels MG, Sánchez PJ, Bernstein DI, Britt WJ, Fowler KB; National Institute on Deafness and Other Communication Disorders CMV and Hearing Multicenter Screening (CHIMES) Study. 2010. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA 303:1375-1382.
3. Bradford RD, Cloud G, Lakeman AD, Boppana S, Kimberlin DW, Jacobs R, Demmler G, Sanchez P, Britt W, Soong SJ, Whitley RJ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. 2005. Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system. J Infect Dis 191:227-233.
4. Britt W. 2015. Controversies in the natural history of congenital human cytomegalovirus infection: The paradox of infection and disease in offspring of women with immunity prior to pregnancy. Med Microbiol Immunol 204:263-271.
5. Brogly S, Read JS, Shapiro D, Stek A, Tuomala R. 2007. Participation of HIV-infected pregnant women in research in the United States. AIDS Res Hum Retroviruses 23:51-53.
6. Bryson YJ, Mirochnick M, Stek A, Mofenson LM, Connor J, Capparelli E, Watts DH, Huang S, Hughes MD, Kaiser K, Purdue L, Asfaw Y, Keller M, Smith E; PACTG 353 Team. 2008. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin Trials 9:115-125.
7. Cannon MJ, Griffiths PD, Aston V, Rawlinson WD. 2014. Universal newborn screening for congenital CMV infection: What is the evidence of potential benefit? Rev Med Virol 24:291-307.
8. Centers for Disease C, Prevention. 2014. Revised surveillance case definition for HIV infection-United States, 2014. MMWR Recomm Rep 63:1-10.
9. Chaudhuri S, Lowen B, Chan G, Davey A, Riddell M, Guilbert LJ. 2009. Human cytomegalovirus interacts with toll-like receptor 2 and CD14 on syncytiotrophoblasts to stimulate expression of TNFalpha mRNA and apoptosis. Placenta 30:994-1001.
10. Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, Rekacewicz C, Newell ML, Delfraissy JF, Cunningham-Schrader B, Mirochnick M, Sullivan JL; International PACTG 316 Team. 2002. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: A randomized trial. JAMA 288:189-198.
11. Doyle M, Atkins JT, Rivera-Matos IR. 1996. Congenital cytomegalovirus infection in infants infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 15:1102-1106.
12. Duryea EL, Sánchez PJ, Sheffield JS, Jackson GL, Wendel GD, McElwee BS, Boney LF, Mallory MM, Owen KE, Stehel EK. 2010. Maternal human immunodeficiency virus infection and congenital transmission of cytomegalovirus. Pediatr Infect Dis J 29:915-918.
13. Erice A, Borrell N, Li W, Miller WJ, Balfour HH, Jr. 1998. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J Infect Dis 178:531-534.
14. Frederick T, Homans J, Spencer L, Kramer F, Stek A, Operskalski E, Kovacs A. 2012. The effect of prenatal highly active antiretroviral therapy on the transmission of congenital and perinatal/early postnatal cytomegalovirus among HIV-infected and HIV-exposed infants. Clin Infect Dis 55:877-884.
15. Gantt S, Carlsson J, Ikoma M, Gachelet E, Gray M, Geballe AP, Corey L, Casper C, Lagunoff M, Vieira J. 2011. The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro. Antimicrob Agents Chemother 55:2696-2703.
16. Gantt S, Gachelet E, Carlsson J, Barcy S, Casper C, Lagunoff M. 2015. Nelfinavir impairs glycosylation of herpes simplex virus 1 envelope proteins and blocks virus maturation. Adv Virol 2015:687162.
17. Gindes L, Teperberg-Oikawa M, Sherman D, Pardo J, Rahav G. 2008. Congenital cytomegalovirus infection following primary maternal infection in the third trimester. BJOG 115:830-835.
18. Griffiths PD, Baboonian C. 1984. A prospective study of primary cytomegalovirus infection during pregnancy: Final report. Br J Obstet Gynaecol 91:307-315.
19. Guibert G, Warszawski J, Le Chenadec J, Blanche S, Benmebarek Y, Mandelbrot L, Tubiana R, Rouzioux C, Leruez-Ville M; French Perinatal Cohort. 2009. Decreased risk of congenital cytomegalovirus infection in children born to HIV-1-infected mothers in the era of highly active antiretroviral therapy. Clin Infect Dis 48:1516-1525.
20. Hamilton ST, Scott G, Naing Z, Iwasenko J, Hall B, Graf N, Arbuckle S, Craig ME, Rawlinson WD. 2012. Human cytomegalovirus-induces cytokine changes in the placenta with implications for adverse pregnancy outcomes. PLoS ONE 7:e52899.
21. Hernando S, Folgueira L, Lumbreras C, San Juan R, Maldonado S, Prieto C, Babiano MJ, Delgado J, Andres A, Moreno E, Aguado JM, Otero JR. 2005. Comparison of cytomegalovirus viral load measure by real-time PCR with pp65 antigenemia for the diagnosis of cytomegalovirus disease in solid organ transplant patients. Transplant Proc 37:4094-4096.
22. Kalu NN, Desai PJ, Shirley CM, Gibson W, Dennis PA, Ambinder RF. 2014. Nelfinavir inhibits maturation and export of herpes simplex virus 1. J Virol 88:5455-5461.
23. Khamduang W, Jourdain G, Sirirungsi W, Layangool P, Kanjanavanit S, Krittigamas P, Pagdi K, Somsamai R, Sirinontakan S, Hinjiranandana T, Ardonk W, Hongsiriwon S, Nanta S, Borkird T, Lallemant M, McIntosh K, Ngo-Giang-Huong N; Program for HIV Prevention and Treatment (PHPT) Study Group. 2011. The interrelated transmission of HIV-1 and cytomegalovirus during gestation and delivery in the offspring of HIV-infected mothers. J Acquir Immune Defic Syndr 58:188-192.
24. Kilewo C, Karlsson K, Ngarina M, Massawe A, Lyamuya E, Swai A, Lipyoga R, Mhalu F, Biberfeld G; Mitra Plus Study Team. 2009. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: The Mitra Plus study. J Acquir Immune Defic Syndr 52:406-416.
25. Kimberlin DW, Acosta EP, Sánchez PJ, Sood S, Agrawal V, Homans J, Jacobs RF, Lang D, Romero JR, Griffin J, Cloud GA, Lakeman FD, Whitley RJ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. 2008. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 197:836-845.
26. Kovacs A, Schluchter M, Easley K, Demmler G, Shearer W, La Russa P, Pitt J, Cooper E, Goldfarb J, Hodes D, Kattan M, McIntosh K. 1999. Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric pulmonary and cardiovascular complications of vertically transmitted HIV Infection Study Group. N Engl J Med 341:77-84.
27. Lorenzoni F, Lunardi S, Liumbruno A, Ferri G, Madrigali V, Fiorentini E, Forli F, Berrettini S, Boldrini A, Ghirri P. 2014. Neonatal screening for congenital cytomegalovirus infection in preterm and small for gestational age infants. J Matern Fetal Neonatal Med 27:1589-1593.
28. McCormack SA, Best BM. 2014. Protecting the fetus against HIV infection: A systematic review of placental transfer of antiretrovirals. Clin Pharmacokinet 53:989-1004.
29. Nakamura Y, Sakuma S, Ohta Y, Kawano K, Hashimoto T. 1994. Detection of the human cytomegalovirus gene in placental chronic villitis by polymerase chain reaction. Hum Pathol 25:815-818.
30. Nelson CT, Istas AS, Wilkerson MK, Demmler GJ. 1995. PCR detection of cytomegalovirus DNA in serum as a diagnostic test for congenital cytomegalovirus infection. J Clin Microbiol 33:3317-3318.
31. Razonable RR. 2011. Rare, unusual, and less common virus infections after organ transplantation. Curr Opin Organ Transplant 16:580-587.
32. Reitter A, Buxmann H, Haberl AE, Schlosser R, Kreibich M, Keppler OT, Berger A. 2015. Incidence of CMV co-infection in HIV-positive women and their neonates in a tertiary referral centre: A cohort study. Med Microbiol Immunol [Epub ahead of print].
33. Revello MG, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E, Kustermann A, Guaschino S, Vergani P, Todros T, Frusca T, Arossa A, Furione M, Rognoni V, Rizzo N, Gabrielli L, Klersy C, Gerna G; CHIP Study Group. 2014. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 370:1316-1326.
34. Ross SA, Novak Z, Fowler KB, Arora N, Britt WJ, Boppana SB. 2009. Cytomegalovirus blood viral load and hearing loss in young children with congenital infection. Pediatr Infect Dis J 28:588-592.
35. Roxby AC, Atkinson C, Asbjörnsdóttir K, Farquhar C, Kiarie JN, Drake AL, Wald A, Boeckh M, Richardson B, Emery V, John-Stewart G, Slyker JA. 2014. Maternal valacyclovir and infant cytomegalovirus acquisition: A randomized controlled trial among HIV-infected women. PLoS ONE 9:e87855.
36. Schafer P, Tenschert W, Cremaschi L, Gutensohn K, Laufs R. 1998. Utility of major leukocyte subpopulations for monitoring secondary cytomegalovirus infections in renal-allograft recipients by PCR. J Clin Microbiol 36:1008-1014.
37. Schleiss MR. 2005. Antiviral therapy of congenital cytomegalovirus infection. Semin Pediatr Infect Dis 16:50-59.
38. Slyker JA, Lohman-Payne BL, John-Stewart GC, Maleche-Obimbo E, Emery S, Richardson B, Dong T, Iversen AK, Mbori-Ngacha D, Overbaugh J, Emery VC, Rowland-Jones SL. 2009. Acute cytomegalovirus infection in Kenyan HIV-infected infants. Aids 23:2173-2181.
39. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Downloaded from http://aidsinfo.nih.gov/guidelines on 11/4/2015
40. Yan Z, Bryant KF, Gregory SM, Angelova M, Dreyfus DH, Zhao XZ, Coen DM, Burke TR Jr, Knipe DM. 2014. HIV integrase inhibitors block replication of alpha-, beta-, and gammaherpesviruses. MBio 5:e01318-e01314.